BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass. and BEIJING, China, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. BGNE HKEX: 06160))), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the 31^st Annual Piper Jaffray Healthcare Conference in New York, NY. The presentation is scheduled for 9:30 a.m. ET on Tuesday, December 3, 2019.

A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.

About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 3,000 employees in the United States, China, Australia, and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. In the United States, BeiGene markets and distributes BRUKINSA™ (zanubrutinib) and in China, the Company markets ABRAXANE^® (nanoparticle albumin–bound paclitaxel), REVLIMID^® (lenalidomide), and VIDAZA^® (azacitidine) under a license from Celgene Corporation.ⁱ

Investor Contact                                         
Craig West                                                    
+1 857-302-5189                                          
ir@beigene.com                                          

Media Contact
Liza Heapes
+1 857-302-5663
media@beigene.com

__________________________
ⁱ ABRAXANE^®, REVLIMID^® and VIDAZA^® are registered trademarks of Celgene Corporation.